Spatio-temporal effects of an urban development announcement and its cancellation on house prices: A quasi-natural experiment

We use a spatio-temporal autoregressive difference-in-differences (SDID) framework to assess the strength of the effect, distributed across space and time, of announcements associated with urban development on house prices. We use a quasi-natural experiment of a large-scale urban redevelopment project in Seoul, South Korea, first announced in 2007 and cancelled six years later without any construction having taken place. Using a rich dataset comprising of 21,200 apartment transactions between 2006 and 2015, we find that the development announcement effect accounts for an increase in apartment transaction prices by up to 7.3% depending on the location of the property from the project site. Prices decrease by up to 5.2% following the cancellation of the project. The SDID captures significant spatial autoregressive effects accounting for up to 15% of the changes in transaction prices, reducing the announcement effects from a standard DID model

Imatinib as the first and only treatment in Europe for adult patients at significant risk of relapse following gastrointestinal stromal tumor removal

F Duffaud, S Salas, T Huyn, JL DevilleLa Timone University Hospital, Marseille, FranceAbstract: Mutations of the KIT gene are the molecular hallmark of most gastrointestinal stromal tumors (GISTs). GIST has become a model for targeted treatment of solid tumors, imatinib becoming the standard first-line treatment of these tumors in the advanced/metastatic phase. Because of the efficacy of imatinib treatment in the advanced setting, its role following resection of a primary non-metastatic GIST was investigated. The recently published phase III, doubleblind, placebo-controlled, multicenter ACOSOG Z9001 study showed that adjuvant therapy is safe, and significantly improves recurrence-free survival compared to placebo when given after resection. To what extent imatinib will improve overall survival has yet to be answered. What is clear is that high-risk GIST patients definitely need adjuvant therapy, and that 1 year of imatinib is not enough for the patients who do need it. The questions of optimal duration of imatinib treatment in the adjuvant setting, adequate selection of risk patients and effect of imatinib on overall survival are currently being studied.Keywords: GIST, gastrointestinal stromal tumors, imatinib, adjuvant therap

Validation d’un questionnaire d’évaluation de l’exacerbation dans la BPCO : l’Exascore

* Autre titre : Validation of an evaluation questionnaire for COPD acute exacerbations (Exascore)* Article disponible en ligne à l'adresse : https://www.sciencedirect.com/science/article/pii/S0761842515003290?via%3DihubInternational audienceAu cours de la BPCO, l’identification précoce d’une exacerbation permet de mieux la gérer. Cette étude avait pour objectif de développer et valider un questionnaire court destiné aux patients, à leur entourage et aux soignants, aidant au diagnostic d’une exacerbation : l’Exascore